Development and Ex vivo evaluation of Rasagiline Mesylate mucoadhesive microemulsion for intranasal delivery using Box-Behnken design
Rasagiline mesylate (RM), an irreversible, selective inhibitor of MAO-B enzyme, is used in the treatment of Parkinson’s disease as oral tablets. It has low oral bioavailability (36%) due to hepatic first pass metabolism. Oral route of administration is associated with nausea and vomiting. Hence present research work was aimed to develop intranasal RM- loaded mucoadhesive microemulsions for brain targeting via olfactory pathway. The microemulsions were developed using Box Behnken design and evaluated for globule size, PDI, Zeta potential, pH, viscosity and ex vivo permeation on excised porcine nasal mucosa. Based on drug solubility, Capmul MCM, Tween 20 and Transcutol P were selected as oil, surfactant and cosurfactant respectively. Microemulsions were prepared by water titration method. Pseudoternary phase diagrams were constructed and the levels of surfactants, oil were selected. The influence of independent variables such as oil, Smix and water on responses size, zeta potential and flux were studied with the help of polynomial equations, contour plots and 3D response surface plots generated by design expert software. Optimized microemulsion formulation (ME18) was composed of oil (Capmul MCM), Smix (Tween 20: Transcutol P; 1:1), water and drug in the ratio 5:42:65:5.The globule size, zeta potential and flux of the optimized microemulsion was 150 nm, -29.6 mV and 291.7 μg/cm2/h respectively. Mucoadhesive agent (Chitosan) was added at 0.5% concentration to optimized microemulsion formulation (MME18). The size, zeta potential and flux of the MME18 was 176.4 nm, 12.1 mV and 323.1 μg/cm2/h respectively. The flux of ME18 and MME 18 was significantly higher than drug solution. The enhancement ratio of MME 18 was 4.2 times to that of drug solution, indicating potential advantage of microemulsion formulation.
Collaborators IP. “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of disease study 2015”. Lancet 388.10053(2016):1545–602.online.
CollaboratorsMCOD. “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of disease study 2015”. Lancet 388.10053(2016):1459–544.online.
Clarke CE. “Clinical review-Parkinson's disease”.British Medical Journal-International Edition 335.7617(2007):441-4.online
Taylor JP, J Hardy, KH Fisch beck. “Toxic proteins in neurodegenerative disease”. Science 296.5575(2002):1991-5.online.
Schapira AH. “Present and future drug treatment for Parkinson’s disease”. Journal of Neurology, Neurosurgery & Psychiatry. 76.11(2005):1472-8.online.
Gallagher DA, A Schrage. “Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease”. CNS drugs 22.7(2008):563-86.online.
Parkinson Study Group. “A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study”.Archives of Neurology 62.2(2005): 241.online.
Fernandez M, S Negro, K Slowing, A Fernandez-Carballido, E Barcia. “An effective novel delivery strategy of rasagiline for Parkinson's disease”. International journal of pharmaceutics 419.1(2011):271-80.online.
Wen Z, Z Yan, K Hu, Z Pang, X Cheng, L Guo, Q Zhang, X Jiang, L Fang, R Lai. “Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration”. Journal of controlled release 151.2(2011):131-8.online
Konda RK, BR Chandu, BR Challa, CB Kothapalli. “Bio-analytical method development and validation of Rasagiline by high performance liquid chromatography tandem mass spectrometry detection and its application to pharmacokinetic study”. Journal of pharmaceutical analysis 2.5(2012):342-9.online
Anjali Devi N, J Krishnaveni. “Development and Ex-Vivo evaluation of atorvastatin microemulsions for transdermal delivery using Box-Behnken Design”. International Journal of Pharmacy and Biological Sciences, 8.2(2018): 81-93.online
Kumar P, KL Mittal, Kegel K.Willem, G Theo J Overbeek, NW Henk. Lekkerkerker. “Handbook of microemulsion science and technology”.CRC press (1999):13-44 .print.
Box GE, DW Behnken.” Some new three level designs for the study of quantitative variables”.Technometrics 2.4(1960):455-75. online
Srividya R, J Krishnaveni. “Development of carbamazepine mucoadhesive microemulsions for brain targeting: pharmacodynamic evaluation”. International Journal of Pharmacy and Biological Sciences 8.3(2018):240-252.online
Haque S, Md Shadab, M Fazil, M Kumar, JK Sahni, J Ali, and S Baboota. “Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation”.Carbohydrate polymers 2012; 89.1(2012):72-9.online
Kesavan K, S Kant, PN Singh, JK Pandit. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Current eye research. 38.3(2013):342-52.online
Kreuter J, J Swarbrick, JC Boylan. D Marcel,” Encyclopedia of pharmaceutical technology”. New York. (1994):165-90.print
Aslan N, Y Cebeci. “Application of Box–Behnken design and response surface methodology for modeling of some Turkish coals”. Fuel. 86.2(2007):90-7.online
Lehr CM, JA Bouwstra, EH Schacht, HE Junginger. “In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers”. International journal of Pharmaceutics 78.3(1992):43-8.online
Sathyamoorthy N, D Magharla, P Chintamaneni, S Vankayalu. “Optimization of paclitaxel loaded poly (ε-caprolactone) nanoparticles using Box Behnken design”. Beni-Suef University journal of basic and applied sciences 6.4(2017):362-73.online
Chen H, X Chang, T Weng, X Zhao, Z Gao, Y Yang, H Xu, X Yang. “A study of microemulsion systems for transdermal delivery of triptolide”. Journal of controlled release. 98.3(2004):427-36.online
Aranaz I, M Mengíbar, R Harris, I Panos, B Miralles, N Acosta, G Galed, A Heras. “Functional characterization of chitin and chitosan”. Current chemical biology 3.2(2009):203-30.online
Copyright (c) 2019 International Journal of Bio-Pharma Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.